Skip to main content

TG Therapeutics

TG Therapeutics Inc is a commercial-stage biopharmaceutical enterprise headquartered in New York City, New York. The company focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its primary commercial product is ublituximab, a targeted monoclonal antibody therapy approved for treating multiple sclerosis and related conditions. Principal revenue is derived from direct commercial product sales of its approved pharmaceutical therapeutics. The enterprise serves clinical physicians, specialty treatment centers, and healthcare patients across North America. TG Therapeutics Inc is publicly traded on the Nasdaq Stock Market.

7 of the funds FundTelligence covers report a position in TG Therapeutics.

Legal name
TG Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
7
Exposure themes
Autoimmune diseases, Treatment, Women's Health

Funds holding TG Therapeutics

Loading...